AQR Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

AQR Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$248K	Buy	46,109 +31,811	+222%	+$146K	﹤0.01%	3503
2025 Q4	$51K	Buy	14,298 +888	+7%	+$2.82K	﹤0.01%	3509
2025 Q3	$38.9K	Buy	+13,410	New	+$45.8K	﹤0.01%	3431
2024 Q4	–	Sell	-13,143	Closed	-$44K	–	2873
2024 Q3	$44K	Buy	+13,143	New	+$47.7K	﹤0.01%	2713
2023 Q4	–	Sell	-30,353	Closed	-$91.1K	–	2332
2023 Q3	$91.1K	Sell	30,353 -3,237	-10%	-$11K	﹤0.01%	2238
2023 Q2	$126K	Sell	33,590 -103,491	-75%	-$387K	﹤0.01%	2127
2023 Q1	$459K	Sell	137,081 -13,807	-9%	-$56K	﹤0.01%	1809
2022 Q4	$726K	Buy	150,888 +120,376	+395%	+$609K	﹤0.01%	1676
2022 Q3	$174K	Sell	30,512 -77,785	-72%	-$595K	﹤0.01%	2061
2022 Q2	$769K	Sell	108,297 -173,178	-62%	-$1.18M	﹤0.01%	1524
2022 Q1	$2.03M	Buy	+281,475	New	+$1.91M	﹤0.01%	1168

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AQR Capital Management's AVIR Position: Q1 2026 in Review

AQR Capital Management increased its Atea Pharmaceuticals (AVIR) stake by 222% in Q1 2026, buying an estimated $146K and bringing the position to 46,109 shares worth $248K. The position accounts for ﹤0.01% of the portfolio, ranked #3503.

AQR Capital Management first reported a position in AVIR in Q1 2022 and has held it in 11 quarters since. The position peaked at $2.03M in Q1 2022. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

AQR Capital Management held 46,109 shares of Atea Pharmaceuticals worth $248K as of Q1 2026.
AQR Capital Management bought 31,811 Atea Pharmaceuticals shares in Q1 2026, an estimated $146K.
Atea Pharmaceuticals made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #3503 holding.
AQR Capital Management first reported a position in Atea Pharmaceuticals in Q1 2022 and has held it in 11 quarters since.
AQR Capital Management's Atea Pharmaceuticals position peaked at $2.03M in Q1 2022.
127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.